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Temporal and spatial concentrations of several pharmaceuticals and personal care products 
(PPCPs), and endocrine disrupting compounds (EDCs) are predicted in the Grand River 
watershed using a novel version of the PhATE (Pharmaceutical Assessment and Transport 
Evaluation) model code, which is adapted to explicitly consider Canadian conditions. Specific 
PPCPs and EDCs previously measured in the Grand River watershed in Ontario, Canada, are 
selected as the target compounds for this study. Due to observed seasonal variability in climate, 
hydrology, and pharmaceutical loadings at the case study location, predicting seasonal 
concentrations of each chemical is expected to improve simulation results and the PhATE model 
is modified accordingly. In this regard, required seasonal hydrological parameters (i.e. flow rate 
and velocity) are estimated based on site data. Furthermore, chemical loss parameters (i.e. in-
stream decay, human loss, and removal efficiency of treatment plants) are extracted from the 
literature and then calibrated to observed seasonal behaviour. Calibration parameters for the case 
study include in-stream decay, human loss, and removal efficiency of three different types of 
treatment plants. Simulated concentrations are validated by comparing them with measured data 
at two previously sampled locations in the Grand River. In general, the PhATE model, when 
modified to account for seasonal variability, accurately simulates pharmaceutical concentrations 
in the Grand River.  
The validated PhATE model is used in a predictive mode to identify streams and stream 
segments with high potential risk of being exposed to the selected PPCPs and EDCs in the 
watershed in different seasons. Results suggest that a portion of the Grand River extending from 
the effluent of Waterloo and Kitchener wastewater treatment plants down to the municipality of 
Brantford is likely to be at higher risk, relative to other portions of the watershed. Moreover, the 
potential for PPCP toxicity to aquatic species is assessed using the maximum simulated 
concentrations for the Grand River watershed. According to regulatory guidelines developed by 
the European Union (EU), most of PPCPs are predicted to be at concentrations that require 
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Chapter 1  
Introduction  
1.1 Background 
Pharmaceuticals, personal care products (PPCPs) and endocrine disrupting compounds (EDCs) 
are chemicals used extensively for day-to-day treatment, prevention, and beautification. They 
have been identified as significant chemical pollutants in the aquatic environment [1]. Previous 
studies of various industrialized and industrializing nations have reported detectable amounts of 
PPCPs and EDCs in surface and ground waters, drinking water, and the effluent of sewage 
treatment plants [2-7]. Canadian watersheds are similarly affected [5-10], although detected 
concentrations have generally been low, i.e., between nanograms and micrograms per litre [5, 11, 
12]. However, even at low concentrations, the continual discharge of these chemicals into the 
environment may have adverse health effects on aquatic biota, such as feminization of various 
species [13, 14]. Therefore, the fate and transport of PPCPs and EDCs in varying environments 
has emerged as an important research topic [13, 15].  
Identification and detection of PPCP and EDC compounds in natural systems requires 
highly sensitive instruments that consume considerable time and money. Therefore, there has 
been an increasing interest in the development of models capable of reliably predicting the fate 
of pharmaceuticals. Reliable models should exhibit the following characteristics: (1) they should 
adequately replicate historical conditions and/or previously measured concentration data; (2) 
they should generate informative and well-constrained expressions of predictive uncertainty 
and/or the likelihood of interesting outcomes and scenarios; and (3) they should provide useful 
guidance for subsequent data collection and monitoring efforts [16]. In this regard, the GREAT-
ER (Geo-referenced Regional Exposure Assessment Tool for European Rivers) and PhATE 
(Pharmaceutical Assessment and Transport Evaluation) models were developed to estimate the 
concentrations of aquatic chemicals in the surface waters of Europe and the United States, 
respectively [17, 18]. These user-friendly models have led to an improved understanding of 
PPCPs and EDCs in U.S. and European environments [16, 19-21]. However, neither of these 




The primary objective of this thesis was to predict the concentrations of frequently detected 
pharmaceuticals and personal care products in a Canadian watershed using the PhATE model. As 
the inherent seasonality of Canadian environments is substantial, the secondary objective was to 
modify the PhATE model so that it accommodates various sources of seasonal variability in 





Chapter 2  
Literature Review 
2.1 Sources and Occurrence of Pharmaceuticals in Surface Water 
Humans ingest pharmaceuticals and related products almost daily, and a certain fraction of each 
dosage is excreted (i.e. as feces or urine) due to incomplete metabolism in the human body. This 
excreted fraction ultimately discharges to surface waters as (potentially treated) anthropogenic 
waste water [5-7, 15, 22, 23]. In urbanized areas, the primary discharge point is a wastewater 
treatment plant, which will, in general, discharge a combination of treated and untreated 
wastewater into the receiving surface water. Consequently, PPCPs and EDCs are discharged to 
the environment in both unaltered parental and metabolized forms [1, 23-25]. Additional sources 
of pharmaceutical loading include the disposal of unused and expired pharmaceuticals in the 
trash and down drains. Overall, wastewater treatment plants are the single largest source of PPCP 
and EDC loading into surface waters [11, 23, 26-31]. 
As PPCPs and EDCs pass through a given WWTP (Waste Water Treatment Plant), a 
certain amount of removal occurs via the combined processes of biodegradation, mineralization, 
sorption, photo-degradation, and volatilization [6, 10, 31-33]. Of these processes, 
biotransformation has been recognized as the most significant mechanism, while volatilization 
and sorption are thought to play relatively minor roles [31].  
After discharge into surface waters, the relative influence of the various attenuation 
processes is not completely understood and is subject to site-specific conditions. For example, 
photo-degradation can be a potentially significant degradation mechanism during surface water 
transport [32, 34, 35]. However, it has been suggested that photo-degradation may be less 
significant in the Grand River due to the high turbidity of these waters [36]. Furthermore, the 
influence and mechanisms for sorption of PPCPs and EDCs in surface water is at present 
unclear. In general, these hydrophilic compounds will remain in the aqueous phase and are not 
likely to have high sorption capacities [37-39]. However, hydrophobic partitioning is not the 
only critical factor in pharmaceutical sorption – other mechanisms, such as ion exchange, 
hydrogen bonding, and mineral absorption, can also play a significant role [37].  
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2.2 Detection of Pharmaceuticals in Canada 
The presence of pharmaceuticals and personal care products in Canadian surface waters has been 
observed by a number of researchers [5-10, 42, 43]. The most frequently detected compounds 
include ibuprofen, naproxen, sulfachlorpyridazine, gemfibrozil, salicylic acid, carbamazepine, 
bezafibrate, and diclofenac [5, 6, 8-10]. Observed concentrations of PPCPs and EDCs range 
from below detection limits to micrograms per litre [6, 8, 10]. In the Grand River watershed, 
PPCP and EDC concentrations have been detected in the nanogram per litre range [5, 42, 43]. 
Naproxen and ibuprofen have been detected at the highest concentrations, relative to 
other pharmaceutical compounds [8, 10]. Yet these compounds are also associated with the 
highest WWTP reduction, with percent removals ranging from 89% to 99% [6, 10]. Conversely, 
carbamazepine and indomethacin are the most persistent pharmaceuticals and have very low 
WWTP removal efficiency [6, 8].  
2.3 Seasonal Variability in PPCPs Concentration 
Relatively few studies have considered the seasonal variability of PPCP and EDC concentrations 
in the environment [e.g. 42, 43, 44-46]. Nonetheless, these studies suggest that PPCP and EDC 
concentrations are influenced by several seasonally varying factors, including chemical 
consumption, rainfall events, flow rate, and temperature.  
Seasonal factors influencing human use of specific PPCPs include elevated consumption 
of ibuprofen and naproxen during the cold and flu season, and increased usage of DEET during 
the summer months [42, 44, 45]. In contrast to these over-the-counter remedies, gemfibrozil and 
carbamazepine are prescribed drugs for treatment of chronic conditions and are therefore 
consumed at a relatively constant rate throughout the year [44].  
High discharge rates associated with spring melt and seasonal rainfall events may reduce 
the efficiency of treatment plants, resulting in elevated PPCP and EDC loadings in surface water 
[12, 47]. In contrast, summer time exposure of pharmaceuticals to long periods of sunlight may 
increase the removal efficiency of some types of treatment (e.g. lagoons) [8]. 
Although there is some disagreement in the literature (i.e. [10, 44] vs. [47]), there is 
evidence that the removal efficiency of treatment plants is highly dependent upon temperature 
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and is likely to be lowest during the winter. Furthermore, in surface waters and other natural 
systems, temperature can significantly influence biodegradation, photolysis and sorption [48]. 
For some compounds, such as ibuprofen and naproxen, the different processes are influenced in 
opposing ways such that the overall degradation behaviour does not vary significantly across 
seasons [47, 49].  
Observational data suggests that different compounds have different timings with respect 
to the occurrence of peak concentrations in surface waters. Examples of such variability include 
peak concentrations of: (1) ibuprofen and naproxen in the winter and fall [42, 43]; (2) DEET in 
the summer [43]; (3) gemfibrozil in spring and summer [42]; (4) lincomycin HCl in spring and 
fall [42]; and (5) sulfamethoxazole in the summer and fall [42]. Other compounds, including 
carbamazepine, trimethoprim, NP, and bezafibrate have been observed to have relatively 
constant (i.e. non-seasonal) concentrations in surface waters [42, 43].  
2.4 Modelling of Predicted Environmental Concentrations  
As mentioned previously, modelling the transport of pharmaceuticals and personal care products 
as well as predicting their concentrations in surface waters is critical to understanding the 
potential impact of these compounds on the environment. For example, the PhATE 
(Pharmaceutical Assessment and Transport Evaluation) model was developed by the 
Pharmaceutical Research and Manufactures of America (PhRMA) to simulate concentrations of 
active pharmaceutical ingredients in eleven watersheds across the United States [17]. Similarly, 
the GREAT-ER (Geography-Referenced Regional Exposure Assessment Tool for European 
Rivers) model was developed as a means of predicting the concentrations of aquatic chemicals as 
well as the distribution of the concentrations of these compounds in European surface waters 
[18]. These models can be used to estimate the potential risk of aquatic chemicals in the 
environment at both national and regional scales. Furthermore, the models allow for an 
assessment of the relative influence of different biotic and abiotic processes on the elimination of 
PPCP and EDC compounds from surface waters [16, 50]. Lastly, these models can help guide the 
design of a cost-effective field sampling strategy by highlighting the stream segments with 
higher potential risk [19, 50].  
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However, ambiguity in the chemical and physical properties of pharmaceuticals as well 
as uncertainty in the hydrological characteristics of a given watershed can significantly reduce 
the predictive capabilities of the PhATE and GREAT-ER models [19-21]. Furthermore, 
fundamental assumptions made by these models, such as ignoring the release of untreated 
pharmaceuticals from treatment plants during rain events, can cause systematic bias in model 
predictions [17]. Similarly, various parameter assumptions (such as constant treatment removal, 
uniformly distributed pharmaceutical usage, and/or constant and spatially homogeneous first-
order decay) can further degrade model predictive capabilities.  
The PhATE model was chosen in lieu of the GREAT-ER model because a previous 
research agreement allowed for convenient access to PhATE modeling code along with extensive 
documentation, dedicated technical support, and personalized training.  
The PhATE model uses simple mass balance equations applied to a given pharmaceutical 
compound along a given reach or segment of surface water. For each segment, mass enters either 
from WWTP point-sources along the segment or via inflow from upstream segments. Masses 
leave a given segment via first-order in-stream decay, flow diversions, or outflow to a 
downstream segment [17]. The potential mass of PPCPs entering from a given wastewater 
treatment plant is estimated via average annual human usage of the compounds multiplied by the 
size of the population served by the wastewater treatment plant. This maximum potential loading 
is reduced via two loss terms, namely: (1) percent removal by human metabolism; and (2) 
percent removal within the treatment plant [17]. The PhATE model treats each segment of a 
given watershed as a plug-flow system, resulting in the following mass-balance equations: 
                                 (1) 
     
     
           
      
 
         
(2) 
where P is population served by a given treatment plant or zero if no WWTP is present along a 
given reach, Mh is annual pharmaceutical usage per capita (kg/person/year), Lh is percent loss of 
pharmaceuticals by human metabolism (fraction), LWWTP is the percent removal by the treatment 
plant (fraction), MWWTP is the point-source mass loading to the associated surface water segment 
(kg/year), CPEC is predicted environmental concentration of the compound (mg/L), Mo is mass 
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loading from upstream (g/day), K is first-order decay rate constant (day
-1
), tR is travel time (day), 
Mi is point-source mass loading from the i
th 
treatment plant (g/day), ti is travel time from the ith 
plant to the end of the segment (day), and Q is flow rate (m
3
/day). 
The input and output data for the model are saved in the Microsoft Access databases. The 
GIS software is also used to manage the hydrological data for the watershed when graphical 
results need to be shown. 
It is worth noting that the in-stream decay in PhATE is such a single rate constant that 
reflect the total sum of relevant factors like biodegradation, volatilization, sorption to the 
sediment, photodegradation, etc. Also, it is assumed that the entire amount of a compound 
produced by manufacturers in a year is consumed by humans and enters into the surface water 
only via treatment facilities. 
The PhATE model is also summarized in Table ‎2-1 along with the GREAT-ER model. 
As indicated in Table ‎2-1, there are many similarities between the two models and study results 




Table ‎2-1: Comparison of the Features and Capabilities of the PhATE and GREAT-ER models   
 PhATE GREAT-ER 
Watersheds applied On 11 Watersheds in the US On 16 European Watersheds 
Assumptions Uses steady-state deterministic mass balance equations 
Segmentation 
Only the rivers that receive mass of the chemical 
compounds from upstream or WWTPs are 
considered in the model and segmented with 
relatively constant characteristics 
All rivers in the watershed are considered in 
the model and segmented with relatively 
constant characteristics 
Mixing in the system 
Rivers are considered as plug flow, and lake and reservoirs are considered as completely mixed 
tanks 
Basic Input Parameters 
Usage per capita, in-stream first-order loss, human loss, removal efficiency for each WWTP 
treatment type loss. 
Parameters Distribution Not directly supported 
Distribution of the parameters can be 
specified by the user ((i.e. normal, 
logarithmic or uniform)) 
Hydrological Regime Deterministic(mean flow and low flow) 
Stochastic (Monte-Carlo to generate variation 
in flow and velocity)  
Data Storage MS Access, GIS GIS and DBF 
Adding New Watershed Requires several changes in MS Access 




2.5 Toxicity of Pharmaceuticals to Aquatic Organisms 
Because of the physio-chemical properties of PPCPs, they have the potential to adversely affect 
aquatic life via both acute and chronic effects [51-54]. However, it is likely that chronic effects 
present the more significant health risk [54, 55]. In this regard, understanding the full impact of 
long-term exposure to mixtures of PPCPs and their degradation products is the focus on ongoing 
research [51, 56, 57]. The toxicity of chemicals is typically measured in terms of an ―Effect 
Concentration‖ (EC), where EC50 refers to the concentration at which 50% of dosed organisms 
die or are adversely impaired; and the Lowest Observed Effect Concentration (LOEC) is the 
minimum dosage at which any adverse effect is observed. Several studies have suggested Effect 
Concentrations for various PPCPs and with respect to various aquatic species [51-53, 56-60] – 
relevant summary information is provided in Table ‎2-2. Ibuprofen and carbamazepine are 
associated with the lowest Effect Concentration values – just 10 ng/L of these compounds can 
alter the behaviour of certain aquatic species [60].  
Table ‎2-2: Toxicity of PPCPs on Aquatic Species 
Compound Species Toxicological endpoint Effect Concentration Reference 
ibuprofen Fish , Japanese medaka - 1-100 μg/L [56] 
ibuprofen Gammarus pulex - 10 ng/L [60] 
ibuprofen H. attenuate LOEC 1 mg/L [54] 
naproxen H. attenuate EC50 2.6 mg/L [54] 
naproxen C. dubia EC50 0.33 mg/L [61] 
carbamazepine H. attenuate EC50 3.76 mg/L [54] 
carbamazepine Gammarus pulex - 10 ng/L [60] 
carbamazepine Daphnia pulex - 1 μg/L [59] 
gemfibrozil H. attenuate LOCE 1 mg/L [54] 
gemfibrozil H. attenuate EC50 1.76 mg/L [54] 
gemfibrozil C.dubia EC50 0.53 mg/L [61] 
bezafibrate H. attenuate LOEC 1 mg/L [54] 
bezafibrate C.dubia LOEC 0.047 mg/L [61] 
nonylphenol Fish, rainbow trout EC50 0.22 mg/L [52] 
sulfamethoxazole C. dubia EC50 0.21 mg/L [61] 
sulfamethoxazole Algae P. subcapitata EC50 0.52 mg/L [61] 
sulfamethoxazole Daphnia - 1-10 μg/L [51] 
trimethoprim Daphnia - 1-10 μg/L [51] 
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Chapter 3  
Methodology and Case Study  
The PhATE model was adapted to account for Canadian conditions and applied to the Grand 
River watershed in Ontario, Canada. The basic PhATE model was modified so that various 
physical, chemical, and hydrological factors were allowed to vary with the seasons (i.e., spring, 
summer, fall, and winter). Seasonal hydrological parameters were estimated directly using flow 
rate values reported by the Grand River Conservation Authority (GRCA) and the Water Survey 
of Canada (WSC). Physical and chemical parameters were extracted from the literature and 
subsequently calibrated to a split-sample subset of available observation data for the Grand River 
watershed. Observation data not used for calibration served as the basis for subsequent model 
validation, which verified the ability of a calibrated model to adequately predict PPCP 
concentrations. In addition, the sensitivity of the model output to various parameters was 
analyzed in order to identify the most influential parameters for predicting PPCP concentrations.  
Following validation of the modified PhATE model, seasonally varying concentrations of 
PPCPs were predicted for the entire Grand River watershed. This allowed for identification of 
those portions of the watershed which are likely to contain the highest PPCP concentrations, 
thereby representing the highest risk areas in terms of negatively impacting aquatic ecosystems. 
Finally, in order to assess the toxicity potential of the selected compounds, the maximum 
predicted concentrations of PPCPs throughout the watershed were compared to corresponding 
minimum effect concentrations reported in the literature. 
The organization of the reminder of the thesis is as follows. This chapter introduces the 
Grand River watershed case study and PPCPs relevant to the Grand River watershed. Also, in 
this chapter, the feasible ranges for the associated model parameters are presented and each 
compound is briefly introduced. The estimation of hydrological data for the Grand River 
watershed is explained in ‎Chapter 4. The numerical experiments including simulation of 
concentrations of the PPCPs and sensitivity analysis, calibration, and validation of the 
parameters are presented in ‎Chapter 5. The results of the numerical experiments are reported in 




3.1 Case Study: Grand River 
The Grand River watershed is located in Southwestern Ontario and drains an area of about 6800 
km
2
 from the highlands of Dufferin County to Port Maitland on Lake Erie [9]. The annual 
average precipitation throughout the watershed is 750-1000 mm and the average annual 
temperature is 6.5 
o
C [63]. The Grand River watershed includes the cities of Kitchener, 
Waterloo, Cambridge, Guelph, and Brantford as well as numerous smaller villages and towns. 
The watershed receives treated effluent from wastewater treatment plants, which serve about 
530,000 residents. Surface waters of the watershed also supply drinking water to portions of 
various municipalities [66, 67]. A map of the Grand River watershed is given in Figure ‎3-1. 
A total of forty wastewater treatment plants are located in the watershed. Twenty eight 
are municipal plants that discharge treated effluent into the Grand River and its branches; of 
these, fifteen are advanced tertiary treatment, nine have secondary treatment, and four are 
lagoons [64-66]. The location of wastewater and drinking water treatment plants throughout the 












3.2 Selection of Target Compounds 
In this study, the selection of compounds was motivated by the following criteria: (1) the 
presence of the compounds in Canadian surface waters at relatively high concentrations; (2) high 
usage of the selected pharmaceuticals by the Canadian population; and (3) the availability of 
seasonal measured data in the watershed, thereby facilitating a robust assessment of the model. 
The considered PPCPs and EDCs included: ibuprofen, naproxen, carbamazepine, gemfibrozil, 
sulfamethoxazole, trimethoprim, bezafibrate, nonylphenol (NP), and N,N-diethyl-m-toluamide 
(DEET). Table ‎3-1 displays a list of the selected compounds and some of their general properties 
including therapeutic classes, molecular weights, octanol-water and sludge-water partitioning 
coefficients, and pKa (acid dissociation constant). 
Table ‎3-1: Properties of the selected PPCPs and EDCs 
Compound Therapeutic Class Molar Mass (g/mol) Log Ko/w Kd (l/kg) pKa 
Ibuprofen Anti-inflammatory 206.28 (C13H18O2) 3.5
a 453.79
a 4.91 
Naproxen Anti-inflammatory 230.259(C14H14O3) 3.18
a 217.2
a 4.15 
Carbamazepine Anti-epileptic 236.269(C15H12N2O) 2.25
a 25.52
a <2 
Gemfibrozil Lipid regulator 250.333(C15H22O3) 4.77
b nd
b 4.7 
Sulfamethoxazole Antibiotic 253.279(C10H11N3O3S) 0.89
b 2.86
b 5.7 
Trimethoprim Antibiotic 290.32(C14H18N4O3) 0.91
b 1.17
b 7.3 








DEET Insect repellant 191.27(C12H17NO) 2.02
e 15
a <2 
a. [37];  b. [67];  c. [68];  d. [69];  e. [70] 
 
3.2.1 Chemical and Physical Analysis of the Compounds 
Nearly 65 publications were reviewed to determine various properties of the selected PPCPs and 
EDCs. Interestingly, the available literature suggests significant variability in the removal of 
PPCPs and EDCs by treatment plants. This variation is attributed to the use of different treatment 
processes, variability in the functioning of same or similar processes, and differences in 
wastewater composition (e.g. industrial vs. municipal wastewaters) [12, 29]. For this study, and 
as summarized in Table ‎3-2, parameter ranges were utilized, which spanned all values reported 
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in the literature. However, removal efficiency of bezafibrate and DEET were not available, and a 
full range (0 to 100%) was used. Following that each compound of interest is briefly introduced.  


















Ibuprofen 77 – 100 [6, 31, 44] 72 – 97 [11, 71-77] 81 – 100 
[27, 30, 31, 75, 
78, 79,77] 
Naproxen 90 – 99.8 [6, 31, 44] 32 – 99 
[6, 11, 73-
76] 
50 – 99.8 
[6, 27, 29-31, 75, 
77, 79, 80] 
Carbamazepine 5 – 51 [6, 31, 44] 0 – 53 
[11, 39, 71, 
73, 75-77] 
0 – 60 [27, 30, 31, 75] 
Gemfibrozil 15 – 60 [6, 31, 44] 5 – 81 
[11, 74, 75, 
77] 
55 – 75 [27, 31, 75, 79] 
Sulfamethoxazole 17 – 99 [44, 77] 9 – 99.8 
[71, 73, 77, 
81, 82] 
1 – 99 [27, 30, 81] 
Trimethoprim 65 – 99 [77] 0 – 100 
[20, 73, 75, 
77, 81, 83-
86] 
0 – 99.6 
[20, 27, 30, 75, 
78, 81] 
Bezafibrate 0 – 100* Not-available 0 – 100 [20, 71, 73] 15 – 93 [29] 
NP 0 – 64 [87, 88] 60 – 97 [28, 88-90] 42 – 97 [27, 28, 30, 88] 
DEET 0 – 100* Not-available 0 – 95 [90-92] 45 – 95 [91] 
1Removal efficiency by lagoon, 2Secondary treatment plant removal efficiency, 3Tertiary treatment plant removal efficiency 
  
Table ‎3-2: Literature-derived ranges of parameter values for the selected compounds (Continued)  
Compunds 






Ibuprofen 0.022 – 1.124 [12, 32, 36, 77, 79, 93, 94] 61 – 92 [11, 95] 
Naproxen 0.051 – 11.885 [12, 36, 79, 93, 96-98] 89 – 99 [95, 99] 
Carbamazepine 0.0012 – 0.24 [12, 26, 32, 39, 94] 69 – 87 [39, 95] 
Gemfibrozil 0.0578 – 1.124 [36, 79, 100] 74 – 94 [95, 101] 
Sulfamethoxazole 0.059 – 11.09 [26, 102-104] 80 – 90 [95, 105] 
Trimethoprim 0.0396 – 0.24 [104, 106] 50 – 56 [105] 
Bezafibrate 0 – 0.161 [93, 98] 49 – 50 [11, 95] 
NP 0.007 – 1.44 [89, 107, 108] -  




Carbamazepine is a prescribed drug used in the treatment of epilepsy and bipolar disorder, as 
well as a wide variety of mental disorders. Between 12 to 31 percent of ingested carbamazepine 
is not metabolized and is excreted via feces and urine [39, 95]. Carbamazepine has a low 
octanol-water partition coefficient and is known to be a hydrophilic compound [31, 110]. This 
compound has low photo- and bio-degradation rates in surface waters, with half-lives of 3-100 
days and 24 hours, respectively [26, 32, 94]. Between 10 and 50% removal efficiency during 
wastewater treatment has been reported for carbamazepine [6, 27, 39, 49, 71, 75], with higher 
removal rates found in plants that perform tertiary treatment and/or lagoon treatment. The low 
removal efficiency of carbamazepine is attributed to its low sorption coefficient and low 
biodegradation capacity [39, 80, 110]. In fact, there have been reported cases of higher 
carbamazepine concentrations following wastewater treatment [47]. Such behaviour has also 
been observed with other chemicals, including trimethoprim, sulfamethoxazole, and gemfibrozil 
[6, 81]. Carbamazepine concentrations exhibit significant seasonal variability in the Grand River 
watershed, with higher concentrations detected in the summer and fall seasons [42].   
Ibuprofen 
Ibuprofen is a non-prescription antiphlogistic drug that is used for relieving symptoms of 
arthritis, primary dysmenorrhea, fever, and pain. Excretion rates for non-metabolized ibuprofen 
have been estimated to be 7 and 23 percent via urine and feces, respectively [95]. Over 90% 
removal of ibuprofen via wastewater treatment has been observed in numerous studies [6, 22, 27, 
28, 71, 73]. Given sufficient residence time (i.e. at least 6 hours), complete removal can be 
achieved [22]. In natural waters, additional removal may occur via biodegradation and 
sedimentation [12, 22]. Some researchers argue that acidic pharmaceuticals like ibuprofen are 
likely to have low sorption capacity in natural systems [88]. Human consumption of ibuprofen is 
markedly seasonal, with peak usage occurring in the winter. Additionally, there is evidence that 





Naproxen is a non-steroidal anti-inflammatory drug (NSAID) used for the relief of pain, fever, 
inflammation and stiffness. After ingestion, between 1 and 20% of the drug is excreted via urine 
and feces [29, 99]. Wastewater treatment removal percentages for naproxen range from 20 to 
100% [6, 11, 29-31, 44, 49, 73, 74]. In general, degradation of analgesics like ibuprofen and 
naproxen in wastewater treatment is primarily from biodegradation; sorption during primary and 
secondary treatment is insignificant. In natural systems, biodegradation and photolysis are the 
primary pathways for elimination of naproxen [12, 97], and measured photo-degradation half-
lives range from minutes to hours [34, 97, 112], with peak rates occurring in the summer.  
Antibiotics 
Trimethoprim and sulfamethoxazole are antimicrobial drugs used for the treatment of infectious 
diseases in humans. By design, such compounds are not readily biodegradable and relatively low 
(~50%) wastewater treatment removal efficiencies have been reported [28, 102, 106]. However, 
there is evidence of photo-degradation being an important removal process [113, 114] that 
exhibits significant pH sensitivity [103, 115] and seasonal variation.  
Fibrates 
Bezafibrate and gemfibrozil are lipid regulator pharmaceuticals used for the treatment of patients 
who have mixed or combined hyperlipidaemia, a common complication of diabetes [116]. 
Almost 50% of ingested gemfibrozil is partially metabolized an excreted as glucuronides [27]. 
Removal of these compounds via wastewater treatment is very low (~10%) and requires 
significant residence time (i.e. several hundred hours) [116]. While adsorption, biodegradation, 
and hydrolysis of gemfibrozil in natural systems is relatively limited, biodegradation of 
bezafibrate can be significant, with reported half-life values ranging from 4.3 to 8.4 days 
depending on flow velocity [93]. This velocity dependence results in an indirect seasonal 
dependence because distinct seasonal flow patterns have been observed in Canadian surface 
waters. 
NP 
Nonylphenol (NP) and its ethoxylates (NPEs) are widely used surfactants found in soaps, 
detergents, and similar cleaning products. More than half of NP found in the environment is a 
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result of individual consumer use of products containing NP. Concern about the endocrine 
disrupting properties of NP led Environment Canada to introduce national regulations and 
restrictions on the manufacture and importation of NP/NPEs. Consequently, annual NP 
production has reduced from 3.35 million kg in 2003 to 1.03 million kg in 2006. Removal 
efficiency of NP in wastewater treatment plants can be between 60 and 97%, depending on the 
type of treatment [27, 28, 30, 88, 89]. Nonetheless, concentrations of NP in the microgram per 
litre range have been observed in various surface waters [4, 43, 89]. Although biodegradation 
rates for NP in natural systems tend to be low (0.007 to 0.051 day
-1
) [107, 108], photo-




N,N-diethyl-m-toluamide (DEET) is an active ingredient of most commercial insect repellents 
marketed in North America. Approximately 80% of DEET that is applied to the human body is 
ultimately discharged to a wastewater system [109]. However, little is known about removal of 
DEET via wastewater treatment or natural processes. For example, a wide range (i.e. between 10 
and 90%) of removal efficiencies has been reported for wastewater treatment of DEET [90-92]. 
Furthermore, mechanisms and rates of elimination of this compound in surface waters have not 
been reported. 
3.2.2 Measured PPCPs and EDCs Data in Grand River 
Previously collected seasonal concentrations of PPCPs and EDCs served as the observational 
data sets utilized in this study for model calibration and validation [42, 43]. One of the data sets 
was collected in the Grand River near Mannheim from 2006 to 2008 [43], while the other data 
set was collected in the Grand River near Mannheim and Holmedale from 2005 to 2006 [42]. 
The average seasonal concentrations of each chemical for these data sets is given in Table ‎3-3 
and Table ‎3-4. The actual daily reported data is given in Appendix A (reproduced, with 
permission, from [42, 43]). 
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Table ‎3-3: Average seasonal concentrations of PPCPs and EDCs in the Grand River near Manheim (from [43] data set) 
Seasons DEET ibuprofen NP naproxen Carbamazepine 
Fall 2006 37.0 9.0 3.5 15.0 11.5 
Winter 2006-7 16.2 96.0 18.6 123.5 28.7 
Spring 2007 50.5 66.6 12.2 65.5 17.7 
Summer 2007 99.9 8.3 20.9 23.7 33.8 
Fall 2007 58.1 39.4 37.8 54.2 30.5 
Winter 2007-8 33.2 50.9 33.5 66.5 14.9 
Spring 2008 32.9 17.3 12.6 36.2 12.1 
Summer 2008 127.4 7.3 2.6 30.0 21.0 
Table ‎3-4: Average seasonal concentration of PPCPs and EDCs in two Grand River locations (from [42] data set) 
Seasons  Ibuprofen Naproxen Carbamazepine Gemfibrozil Bezafibrate Sulfamethoxazole Trimethoprim 
Winter 2005-6 
Mannheim 
23.3 20.4 7.3 1.3 2.5 10 4.0 
Spring 2005-6 14.4 28.7 7.4 1.5 2.5 10 3.1 
Summer2005 12.0 36.5 24.1 2.5 2.5 10 5.4 
Fall2005 28.4 20.6 20.3 2.1 3.4 19.7 7.3 
Winter 2005-6 
Holmedale 
29.1 10.6 15.0 2.4 5.8 10 5.0 
Spring 2005-6 22.2 10.9 16.5 3.5 6.1 15.8 4.2 
Summer2005 6.5 22.4 370.1 3.2 2.5 23.0 4.3 
Fall2005 17.9 32.1 42 3.6 6.6 32.0 4.4 
20 
 
Chapter 4  
Hydrological Data Estimation  
4.1 GIS Data Collection 
The Grand River Conservation Authority (GRCA) provided Geographic Information System 
(GIS) data for the Grand River watershed. Relevant data sets were available from the Map 
Library of the University of Waterloo as well as the GRCA website (www.grandriver.ca). The 
GIS data included information on virtual drainage, sewage treatment plants, water flow stations, 
dams, and sub-catchments. The virtual drainage for the watershed provided not only the drainage 
network but also the Strahler stream ordering (explained in Section ‎4.4 ) of the various stream 
segments. Information on sewage treatment plants consisted of the location of the plants as well 
as the population being served by each plant.  
Following established guidelines [117], only surface waters receiving treated waste 
water, either from a treatment plant or from upstream flow, were included in the PhATE model 
of the Grand River watershed. These ‗primary‘ rivers were divided into 84 segments using 
virtual drainage data. Segmentation was based on the following criteria proposed by BASINS 
(Better Assessment Science Integrating point and Nonpoint Sources) [118]: (1) any significant 
differences in flow rate, channel slope, roughness, or channel geometry; and (2) the presence of 
dams or other obstructions.  
Water Flow Stations 
Numerous flow monitoring stations are located in the Grand River watershed, including 25 
stations operated by the WSC (Water Survey of Canada) and 30 operated by the GRCA (Grand 
River Conservation Authority). Historical flow data from each WSC station was retrieved from 
the Environment Canada website (www.ec.gc.ca/rhc-wsc). However, historical data from the 
GRCA stations was unavailable, with the exception of the data at Doon Station, which was 
provided by Dwight Boyd of the GRCA (personal comm.). The locations of the WSC and GRCA 
monitoring stations are indicated in Figure ‎4-1. Station names and corresponding geographical 
coordinates and record lengths are provided in Appendix B. Data reported for two of the 
monitoring stations (i.e. 2GA027, with only four years of record, and 2GA042, a seasonal 
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monitoring station) was deemed insufficient and these stations were therefore not utilized in this 
study. 
Flow data measured at the WSC stations was used to estimate the hydrological data 
required by PhATE in the remaining un-gauged streams of the watershed (i.e. mean and low 
flow values and mean and low velocities for each stream segment). As can be seen from Figure 
‎4-1, the flow stations are well-distributed throughout the watershed and this allowed for adequate 
interpolation of un-gauged areas. 
 
Figure ‎4-1: Location of the WSC and GRCA monitoring stations in the Grand River watershed     
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4.2 Average and Low Annual Flow Rate 
Flow rates for each stream segment of the watershed were not readily accessible; therefore, it 
was essential to estimate the flow for the entire steam segments in the watershed. Drainage area, 
precipitation, and temperature are the most important variables for estimating average annual 
flow [119]. Of these variables, drainage area is recognized as the most influential factor [120]. 
To illustrate the strong relationship between flow and drainage area in the Grand River 
watershed, the average annual flow obtained from the WSC stations is plotted in Figure ‎4-2 
versus the corresponding drainage area, determined using the geospatial processing features of 
ArcGIS. As shown in Figure ‎4-2, there is an excellent linear relationship between these two 
variables. Two linear regressions were utilized - one regression for segments with a drainage 
area greater than 1,200 km
2
 and another regression for stations associated with a drainage area of 




Figure ‎4-2: The relationship between average annual flow and drainage area in the Grand River 
watershed (a) for segments with drainage area less than 1,200 km
2




The relationship between low annual flow and drainage area is shown in Figure ‎4-3 (see 
next page). The R-squared values for this relationship were not as robust as for the average 
annual flow, but were deemed to be suitable for estimating low flow in un-gauged stream 
segments. Using the regression lines given in Figure ‎4-2 and Figure ‎4-3, annual average flow and 
annual low flow values were estimated for each segment in the watershed as a function of the 
corresponding drainage area. 
 















































Figure ‎4-3: The relationship between low annual flow and drainage area in the Grand River 
watershed (a) for segments with drainage area less than 1,200 km
2
 (b)for segments with drainage area 




4.3 Seasonal Flow 
As described previously, one of the objectives of this research was to apply the PhATE model in 
a manner that accounts for the inherent seasonal variability of Canadian environments. As a 
result, it was necessary to develop additional seasonal (i.e. spring, summer, fall, and winter) 
estimates of average and low flow values for each stream segment. This process, known as 
hydrological seasoning, is described in the following sub-section. 
4.3.1 Hydrological Seasoning  
Before estimating seasonal flows, it was necessary to first define each hydrological season. In 
this regard, a hydrological season was defined as three continuous months of relatively similar 
flow rates. To more readily discern these seasons from the available data, the average daily flow 
of each station was standardized to have a mean of zero and variance of one, using the following 
equation. 
                                                                (3)  
Standardized flow values for the considered WSC stations are plotted in Figure ‎4-4. As 
shown, the lowest flow values occur from June to November, moderate flow values occur from 
December to February, and the highest flow values occur from March to May. Consistent with 
these observed trends, hydrological seasons were defined as follows: winter – December, 
















































January, and February; spring – March, April, and May; summer – June, July, and August; and 





Figure ‎4-4: Determination of hydrological seasons using standardized flow values averaged over all 
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4.3.2 Average Seasonal Flow 
Similar to the estimation of average annual flow, average seasonal flow for each monitoring 
station was plotted against the corresponding drainage area, where average seasonal flows were 
determined by averaging daily flow data for a given hydrological season (see previous section). 
As was done for average annual flow, two linear regressions were calculated, corresponding to 
drainage areas greater than and less than 1,200 km
2
. To address observed flow trends in the 
summer and fall, an additional linear regression was calculated using data for stations with a 
drainage area of less than 200 km
2
. The resulting seasonal relationships between flow and 
drainage area, along with corresponding R-squared values, are given in Table ‎4-1 and graphs of 
each corresponding regression are provided in Appendix C. As shown in Table ‎4-1, drainage 
area is highly correlated with average seasonal flow and the regressions yielded R
2
 values 
ranging from 0.78 to 0.99.  
Table ‎4-1: Linear relationship between average seasonal flow rate (Q) and drainage area (DA), with 
corresponding R-squared values 
Season For segments with DA>1200 km2  For segments with DA<1200 km2  For segments with DA<200 km2  
Winter 
Q = 0.0106 DA + 0.304 
R² = 0.9916 
Q = 0.0116 DA + 0.0442 
R² = 0.9784 
- 
Spring 
Q = 0.0203 DA + 0.2999 
R² = 0.9975 
Q = 0.0211 DA + 0.012 
R² = 0.9688 
- 
Summer 
Q = 0.0056 DA - 0.1916 
R² = 0.9866 
Q = 0.0058 DA - 0.2491 
R² = 0.8744 
Q = 0.0035 DA + 0.0939 
R² = 0.7769 
Fall 
Q = 0.0071 DA + 0.2132 
R² = 0.9887 
Q = 0.0082 DA - 0.1328 
R² = 0.9283 
Q = 0.0068 DA + 0.0321 
R² = 0.8777 
 
4.3.3 Low Seasonal Flow 
A variety of definitions and procedures for determining low flow have been proposed [121]. For 
example, low flow in the United States is generally indicated by either a ―7Q10‖ or ―7Q2‖ value, 
defined as the lowest average flow occurring over a seven day period with a ten (7Q10) or two 
(7Q2) year return interval. Alternatively, low flow can be defined as flow having an exceedance 
probability of some given percentage (e.g. 95% or 90%). In this study, low seasonal flow was 
defined according to a 95% exceedance probability – meaning that 5% of recorded flow values 
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for a given season would be less than or equal to the low flow value and the remaining 95% of 
recorded values would be greater than the low flow value. 
After defining low flow values for each season at the WSC stations, the procedure for 
determining low seasonal flow values for un-gauged segments was analogous to the procedure 
for estimating of the average seasonal flow. Linear regression equations relating low seasonal 
flow and drainage area are given in Table ‎4-2 and further details are provided in Appendix C. As 
shown in Table ‎4-2, the R-squared values ranged from 0.69 to 0.99 and stations with a drainage 
area greater than 1,200 km
2
 exhibit a relatively stronger correlation between flow and drainage 
area. For segments with a small drainage area, the liner regressions given in Table ‎4-2 sometimes 
yielded negative flow values – in such cases, the minimum measured flow value was utilized 
instead. 
Table ‎4-2: Linear relationship between seasonal low flow rate (Q) 
 and drainage area (DA), with corresponding the R-squared values 
Season For segments with DA>1200 km2 For segments with DA<1200 km2 
Winter 
Q = 0.0027 DA - 0.3203 
R² = 0.9883 
Q = 0.0022 DA - 0.1138 
R² = 0.874 
Spring 
Q = 0.0045 DA - 0.573 
R² = 0.9849 
Q = 0.0031 DA - 0.11 
R² = 0.8227 
Summer 
Q = 0.0031 DA - 0.4475 
R² = 0.9747 
Q = 0.0028 DA - 0.3352 
R² = 0.6916 
Fall 
Q = 0.0027 DA - 0.4499 
R² = 0.9844 
Q = 0.0021 DA - 0.2446 
R² = 0.7749 
 
4.4 Velocity 
Along with stream flow, the PhATE model requires information about average and low flow 
velocities for each stream segment in order to generate the travel time of the compounds in the 
surface water (see equation (2) in section ‎2.4 ). For this study, velocity information was inferred 
using available flow data paired with relevant morphologic features of a given stream segment. 
Average Velocity 
The width (W), depth (D) and velocity (V) of a given stream segment have been shown to be 
logarithmically related to stream flow (Q) [122] as given in the following equations:  
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               (4) 
               (5) 
                (6) 
where a, c, k and b, f, m are hydrological coefficients such that a×c×k=1 and b+f+m=1. 
Previous studies of the morphologic features of rivers in Southern Ontario have included 
portions of the Grand River watershed [123]. Table ‎4-3 summarizes the results of these studies, 
and includes location information (in terms of station identifier) along with the estimated values 
for Manning’s n friction factor and hydrological coefficients given in eqns. 4-6.  
To apply equations 4-6 to all segments in the watershed, each stream was classified 
according to its Strahler stream order. The Strahler stream order approach classifies a given 
stream segment based on the number of connecting upstream and downstream branches – when 
streams with the same order intersect, the order of the corresponding downstream segment is 
increased [124]. The Strahler stream order ranges from one (for head water segments) to seven at 
the most downstream pour-point of the Grand River watershed. Strahler stream orders for the 
Grand River watershed are given in Table ‎4-3.  
Stream segments were divided into two categories according to stream order: (1) stream 
order < 4; and (2) stream order > 3. For stream order < 4, velocity relationships developed for 
station numbers 24-26 were applied. For stream order > 3, velocity relationships developed for 
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Low Flow Velocity 
The corresponding velocity in low flow conditions for each stream segment were calculated 
using the following equation [125]: 
                                       
        
         
 





Chapter 5  
Numerical Experiments  
5.1 PhATE Simulation (Uncalibrated) 
As discussed previously, reliably predicting the concentration of pharmaceuticals in surface 
water depends on an adequate assignment of several hydrological and chemical parameters. In 
this study, these required parameters for the PhATE model were classified as being either 
prescribed or estimated parameters. Prescribed parameters included flow and velocity of stream 
segments and annual per capita pharmaceutical usage. Values for these parameters were derived 
from data that was readily available for the Grand River watershed and/or Canada. Conversely, 
appropriate values of estimated parameters (i.e. removal efficiencies of lagoons and secondary 
and tertiary treatment plants, in-stream loss, and human loss) for the given case study were not 
readily available. Thus, an initial survey of the literature was performed in order to establish a 
reasonable range of expected values for these parameters. Subsequent sensitivity analysis 
explored the influence of these parameters on model outputs, and various trial-and-error and 
automated calibration efforts adapted the parameter values to obtain model results that best 
matched observed behaviour in the Grand River watershed.  
Exploring whether the use of seasonal parameters could improve PhATE predictions was 
an important objective of the research. As mentioned in Chapter 4 (Hydrological Data 
Estimation), seasonal low and mean flow and corresponding seasonal velocities were developed 
for each segment of the watershed using available data. These seasonal hydrologic parameters 
were incorporated into four Access database input files, corresponding to one input file per 
season. Also included in each input file were corresponding seasonal estimates of pharmaceutical 
loading and various loss parameters (see Table ‎5-1). Both the loss and loading parameters varied 
according to the type of pharmaceutical compound considered for a given simulation. 
While an initial set of baseline (i.e. uncalibrated) simulations utilized the parameter 
values given in Table ‎5-1, subsequent numerical experiments (i.e. manual calibration, sensitivity 
analysis, and automated calibration) adjusted the various seasonal loss and loading terms in a 
systematic manner. The methodology and rationale for these additional experiments are 
described in the following sections. 
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Table ‎5-1: Seasonal removal efficiency of treatment plants and in-stream decay for the selected 












Winter 99 78 87 0.139 
Spring 88 86 92 0.062 
Summer 77 90 90 0.288 
Fall 94 90 91 0.078 
Naproxen 
Winter 99 62 79 2.66 
Spring 95 73 79 2.66 
Summer 90 74 90 4.62 
Fall 99 69 87 1.39 
Carbamazepine 
Winter 21 4 4 0.001 
Spring 29 4 17 0.082 
Summer 28 21 17 0.072 
Fall 18 11 53 0.009 
Gemfibrozil 
Winter 99 78 87 0.139 
Spring 88 86 92 0.062 
Summer 77 90 90 0.288 
Fall 94 90 91 0.078 
Sulfamethoxazole 
Winter 58 39 56 1.111 
Spring 70 33 56 1.145 
Summer 58 56 40 2.968 
Fall 58 15 70 1.127 
Trimethoprim 
Winter 82 42 55 0.109 
Spring 82 38 41 0.109 
Summer 82 51 35 0.109 
Fall 82 42 53 0.109 
Bezafibrate 
Winter 50 15 58 0.081 
Spring 50 77 58 0.081 
Summer 50 54 58 0.081 
Fall 50 15 58 0.081 
NP 
Winter 32 79 74 0.031 
Spring 32 79 74 0.208 
Summer 32 79 74 0.734 
Fall 32 79 74 0.031 
DEET Annual 50 37 62 0.791 
 
5.2 Manual Calibration 
The uncalibrated PhATE simulations yielded extremely unrealistic predictions for certain 
compounds (e.g., naproxen) when applied to the Grand River watershed. For these compounds, 
and for reasons that are described below, using literature and/or engineering judgment was not an 
effective method for assigning certain parameter values. As a result, such parameters were 
targeted for manual ―trial-and-error‖ calibration. The manual calibration exercise consisted of a 
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series of simulations for each compound. These numerical experiments involved manually 
perturbing selected parameter values and then running the corresponding revised PhATE model. 
The objective of each manual calibration was two-fold: (1) to achieve a better correspondence 
between PhATE outputs (i.e. predicted pharmaceutical concentrations in the various stream 
segments of the Grand River) and previously measured concentrations; and (2) to gain 
preliminary insights about the influence of individual parameters on model predictions. 
To improve the results of the PhATE simulations of NP and DEET in the Grand River 
watershed, the loading terms for these compounds were selected for manual calibration. These 
terms were chosen for manual calibration because their usage in the Grand River watershed is 
not known and uncalibrated values of these terms were assigned using U.S. data for total NP and 
NPE and for DEET. 
For naproxen, the uncalibrated simulation used an average of literature-derived values for 
assigning treatment plant removals and in-stream loss parameters. However, this approach 
yielded PhATE predictions which significantly underestimated naproxen concentrations, relative 
to the measured data – evidently the uncalibrated loss and removal rates were too high. In fact, 
researchers have suggested that chemical removal in Canadian treatment plants is likely to be 
lower than in other countries as the result of the generally colder climate [6]. Therefore, manual 
calibration was applied to these loss terms to explore whether reducing the loss rates to below 
average values (see Table ‎5-2) could improve model predictions. 
In the Grand River watershed, it is reasonable to expect ibuprofen and naproxen usage to 
spike in the winter, and DEET usage to peak in the summer [42, 44, 45]. However, quantitative 
data on seasonal usage of these compounds was not available and as a result the uncalibrated 
simulations did not consider seasonality. This motivated a series of manual calibration 
experiments that considered the influence of markedly different seasonal usage of ibuprofen, 
naproxen, and DEET within the Grand River watershed. For these experiments, the annual usage 
of each compound was divided among the four seasons and the percentages allocated to each 
season were manually calibrated. The resulting estimated per capita usage for each compound is 
given in Table ‎5-3 along with prescribed annual usage values. 
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Table ‎5-2: Low seasonal parameters for naproxen 
Compound Removal by 
Lagoon (%) 
Removal by 
Secondary TP (%) 
Removal by 




Winter 90 32 50 0.060 
Spring 90 42 50 0.060 
Summer 90 37 73 0.040 
Fall 90 32 50 0.051 
 












Ibuprofen 0.008183 0.015285 0.008838 0.002291 0.006219 
Naproxen 0.001825 0.002628 0.002482 0.000730 0.001460 
Carbamazepine 0.000727 0.000727 
Gemfibrozil 0.000126 0.000126 
Sulfamethoxazole 0.000684 0.000684 
Trimethoprim 0.000167 0.000167 
Bezafibrate 4.63E-05 4.63E-05 
NP 0.000905 0.000905 
DEET 0.000752 0.000362 0.000724 0.001200 0.000724 
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5.3 PhATE Parameters Sensitivity Analysis  
A sensitivity analysis (SA) was conducted to evaluate the influence of estimated parameters on 
predicted pharmaceutical concentrations in the surface waters of the Grand River watershed. 
Sensitivity analysis is a procedure for ranking parameters in terms of their overall influence on 
model outputs [126]. Different strategies for sensitivity analysis have been proposed [127-130], 
and this study considered a screening-level global sensitivity analysis technique based on the 
Taguchi design of experiments (TDOE) approach [131-136].  
The Taguchi design of experiments method is a fractional-factorial experimental 
approach that has been a popular tool for tuning various manufacturing processes [133] and has 
recently been adapted for performing sensitivity analyses on model parameters [131, 135]. The 
method requires a series of numerical experiments involving a discrete set of values (levels) for 
the various uncertain parameters (factors). Instead of evaluating all factor-level combinations, 
orthogonal arrays are utilized to define an experimental layout that minimizes computational 
expense while maximizing information gain. To assess the various sensitivities of interest, the 
experimental results can be analyzed quantitatively or graphically. 
For this study, the required TDOE experiments were analyzed using a quantitative 
analysis of variance (ANOVA) approach [132, ch. 7]. In this regard, parameters that explain a 
larger percentage of variation are more influential and will have higher TDOE scores. To set up 
the Taguchi experiments, 4 and 5 levels for each parameter were considered. Given these settings 
and the number of factors (i.e. 5, the number of estimated parameters) the L16 and L25 orthogonal 
arrays were selected for the 4- and 5-level designs, respectively. The results of these SA 
experiments are discussed in Section ‎6.2 . 
5.4 PhATE Auto Calibration 
Automated calibration (also known as parameter estimation) applies an optimization search 
algorithm to adjust uncertain model parameters in order to obtain the best possible 
correspondence between model outputs and historical observation data. Numerous local, global, 
and hybrid search algorithms have been successfully applied to calibrate various environmental 
models (e.g. see [126] for list of alternatives). Use of an automated calibration algorithm requires 
definition of an objective function and in this study the conventional weighted sum of squared 
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residual (WSSR) approach was utilized [137]. The following sub-sections describe the 
optimization software and algorithms utilized in this research. 
OSTRICH 
OSTRICH (Optimization Software Tool for Research In Computational Heuristics) is an open-
source and model-independent code that implements numerous local, global and hybrid search 
algorithms, including non-linear regression, particle swarm optimization, and dynamically 
dimensioned search routines [138]. After linking the OSTRICH toolkit with the PhATE 
modeling system (see below), the DDS algorithm [139] was utilized for performing automated 
calibration.  
To use OSTRICH, it was first necessary to link it with the desired simulation model (i.e. 
PhATE). OSTRICH is specifically designed so that it can easily be linked with models that 
accept and generate text-based input/output files with no user interaction required. However, the 
PhATE model works only through a graphical user interface (GUI) and depends heavily on user-
interaction via various button clicks and dialog windows. Furthermore, the PhATE model utilizes 
the Access Database file format for its output files. As a result, linking OSTRICH with the 
PhATE model was not trivial. Therefore, Webber Chan, a co-op student from the department of 
Software Engineering, was tasked with modifying the OSTRICH software to support the Access 
Database file format. Furthermore, to programmatically manipulate the input of the PhATE 
model, Mr. Chan made use of AutoHotKey – an open-source utility for windows that can 
simulate keystrokes and mouse clicks. Appropriate AutoHotKey scripts were created allowing 
OSTRICH to run the PhATE model without user intervention. 
DDS 
The Dynamically Dimensioned Search (DDS) algorithm was employed for calibration of the 
PhATE model [139]. The DDS algorithm focuses on finding ―good-enough‖ global solutions 
within a specified maximum computational budget. Designed to mimic the trial-and-error 
approach commonly employed by practitioners, DDS may be viewed as a kind of stochastic 
direct search procedure (Tolson, personal communication). The algorithm requires no tuning and 
the search dimension is dynamically refined as optimization proceeds.  
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Chapter 6  
Results and Discussion 
6.1 Simulation Results (Uncalibrated) 
The cumulative distribution of the measured concentrations was used to show the efficiency of 
the model to predict a reliable range of concentration for each season. Figure ‎6-1 shows the 
predicted concentration (PEC) of ibuprofen, the limit of detection (LOD) and the limit of 
quantification (LOQ) along with the empirical cumulative distribution function of the measured 
concentration values. The same plots for the other compounds (i.e. naproxen and carbamazepine, 
NP and DEET) are presented in Appendix D. In these plots, the measured concentrations below 
LOQ were assigned the average of LOQ and LOD, and similarly, measured concentrations 
below LOD were assigned the half the LOD values.  
The plots presented in Figure ‎6-1 and Appendix D demonstrate the following results: 
 For ibuprofen and naproxen, about 50% of measured concentrations in summer, spring, 
and winter fell within the simulated concentrations associated with average seasonal 
mean flow and average seasonal low flow. However, in the fall, only 20-30% of the 
measured concentrations fell within the corresponding simulated concentration range.  
 Simulated concentrations of carbamazepine showed good agreement with the measured 
data. Only one measured data point in the spring and one in the summer exceeded the low 
flow-based simulated concentration. The mean flow concentration in winter and spring 
was simulated less than the LOQ. 
 Conversely, less than 30% of NP measured concentrations were between the simulated 
concentrations, as the measured data distributed widely. 
 For DEET, about 40 to 60 percent of the measured concentrations fell within the 
simulated concentrations in low and mean flow. A small number of measured 
concentrations exceeded the low flow simulated concentration in all seasons, with the 
exception of the measured data in the spring when 20% of the measured data were greater 




Overall, approximately fifty percent of the measured concentrations were between the 
seasonal simulated mean flow concentration and low flow concentration. However, more than 85 
percent of the measured concentrations of the compounds were less than or equal to the seasonal 
simulated low flow concentration. The model tended to over predict concentrations, and where 
model predictions were poorly matched to the measured data, the misfits tended to be due to the 
model over-predicting rather than under-predicting. This trend was attributed to the fact that 
many of the measured concentrations were likely sampled at times when the flow rate was 






Figure ‎6-1: Comparing seasonal simulated concentration of ibuprofen and the seasonal cumulative measured data – PEC: predicted 




















































































































































6.2 Results of PhATE Parameters Sensitivity Analysis 
To assess the sensitivity of the selected PPCPs (i.e. ibuprofen, naproxen, carbamazepine, 
gemfibrozil, sulfamethoxazole, and trimethoprim) concentrations in the surface water to the 
PhATE model parameters, the sum of squared differences (SSD) and the percent contribution 
explained by the sum of squared differences were used. The SSD was defined as the summation 
of squared differences between the average concentrations at different levels and the average 
overall concentrations. The percent contribution, which is the ratio of each SSD to the total SSD, 
normalized the magnitude of the variation. 
As stated in Section ‎5.3 , two Taguchi orthogonal array designs, L‘16 and L‘25, were 
deemed appropriate for sensitivity analysis in this study; therefore, two separate analyses were 
conducted for ibuprofen to compare them and pick the best one (see Figure ‎6-2). The comparison 
showed that, in general, there was an insignificant difference between the two designs; however, 
using L‘16 yielded more reasonable results. For example, the results of the L‘16 experiment were 
more convenient to show whether the given segment received effluent from a specific type of 
treatment plant. Therefore, a sensitivity analysis of each compound was conducted by applying 
the Taguchi method using 4 levels (L‘16).  
For the selected compounds, the percent contribution values and the sum of squared 
differences of each parameter on concentrations are shown in histograms along the Grand River 
segments. The histograms presenting results of the sensitivity analysis for the ibuprofen 
parameters are shown in Figure ‎6-2 and Figure ‎6-3, and the same histograms for the other 
compounds are presented in Appendix E. Parameters with a larger percent of the overall 
variation in the concentrations had a more significant influence on model outputs. The results 
indicated that the upper stream segments of the Grand River were less affected than the 
downstream segments (from segment 36). The downstream segments of the Grand River receive 
the effluent of more populated treatment plants (e.g., Waterloo and Kitchener wastewater 
treatment plants); therefore, parameters are likely to have more considerable influence on the 
concentrations. 
Generally, human loss, which can represent the effect of loading as well, and removal 
efficiency by secondary treatment plants were recognized as parameters with the most significant 
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effect on concentrations of PPCPs. Wastewater treatment removal and loading are suggested to 
have equal effects on all concentrations within the watershed [17]. However, the results of this 
study showed that the treatment plant closest to a segment usually has a greater effect on the 
concentration in comparison with the effect of other treatment plants. Nonetheless, the influence 
of each parameter is highly related to its feasible interval. For example, the concentrations of 
sulfamethoxazole and naproxen with a high in-stream decay value (i.e. higher than 11 day
-1
) 
were considerably affected by in-stream decay rate. This parameter is suggested to have a greater 
effect on low concentrations and a lower effect on high concentrations, which usually occur in 
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6.3 Calibration Results 
Using the DDS optimization algorithm through the OSTRICH interface, the five PhATE model 
parameters (i.e., removal efficiency of lagoon, removal efficiencies of secondary and tertiary 
treatment plants, in-stream decay, and human loss) were seasonally calibrated to obtain model 
results that best matched to the observed concentrations in the Grand River watershed. 





































































for each parameter and using the average parameter values as the initial solution. The calibration 
objective function was defined as minimizing the weighted sum of the squared deviations (errors 
– SSE) of simulated concentration values from measured data. Equal importance (weights) was 
assumed for all observations while calibrating for all compounds except for bezafibrate and 
sulfamethoxazole. For calibration of these two compounds, the measured concentrations above 
the detection limit received a greater weight (i.e., a weight twice as large as the weight of 
observations below the detection limit). 
Two hundred function evaluations were employed in the auto-calibration process. Each 
function evaluation consisted of n PhATE model runs, where n was the number of available 
observations in each season. For example, for the ibuprofen calibration in winter, each function 
evaluation consisted of 20 PhATE model runs, one for each of the input files. Approximately 4 
seconds was the required time for the PhATE model to run on a desktop computer with an Intel® 
Core™i3 CPU (520 @ 2.93GHz). Therefore, each function evaluation, e.g., consisting of 20 
model runs, required about 80 seconds, and a calibration trial with only 200 function evaluations 
required up to 4.5 hours. Going beyond 200 function evaluations was out of the available 
computational budget because there was a considerable number of calibration trials for different 
seasons for each compound and because it was not possible to work with the computer while 
running.  
The sufficiency of using 200 function evaluations was tested using two calibration trials 
with higher numbers of function evaluations, one for ibuprofen in winter (with 2000 function 
evaluations) and another calibration trial for naproxen in fall (with 1400 function evaluations). 
These experiments showed no significant improvement over the experiments with 200 function 
evaluations. The uncalibrated value of SSE (objective function value) for ibuprofen was 296340, 
while after calibration using 200 and 2000 function evaluations, the SSE values reached 6513 
and 6034, respectively. For naproxen, calibration did not improve the SSE significantly, as SSE 
slightly decreased from 15406 uncalibrated to about 11342 and 11237 after calibration with 200 
and 1400 function evaluations, respectively. Figure ‎6-4 and Figure ‎6-5 also graphically compare 






Figure ‎6-4: Measured and simulated concentrations of ibuprofen in winter at sampling time 
 
 






























Calibrated Conc. with 200 trials





























Calibrated Conc. with 200 trials




A composite scaled sensitivities (CSS) analysis was also conducted through OSTRICH on the 
best parameter sets that were found for each compound in each season. The CSS values represent 
the overall sensitivity of the model expressed by each parameter [137]. A high value of CSS 
represents a high sensitivity of the model output to the parameter [52, 85]. The CSS depends on 
the parameter values and might not properly represent the sensitivity of the model to parameters 
with low values or highly correlated parameters [137]. Table ‎6-1 shows the CSS and the 
calibrated parameter values, which were referred to as the most probable seasonal parameters of 
the selected compounds for the case.  
According to the CSS values reported in Table ‎6-1 and similar to the results of the 
sensitivity analysis in section ‎6.2 , human loss had the most significant influence on the 
concentrations of the selected compounds in the surface water. The removal efficiency of the 
secondary treatment plants was the second most important parameter, especially for ibuprofen, 
naproxen, and NP. In-stream decay also significantly affected concentrations of naproxen, 
DEET, trimethoprim.  
As shown in Table ‎6-1, the calibrated human loss values for each compound varied for 
each season, while human loss is expected to remain constant for all seasons. This variation can 
be the result of imperfect modelling and calibration and/or seasonality in loading. As explained 
in Section ‎5.2 (model parameterization for calibration), loading was fixed in the uncalibrated 
step for each season; therefore, seasonality in loading can be partially conveyed by seasonality in 
human loss parameters.  
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To visually compare the performance of the PhATE model before and after calibration, 
the simulated concentrations are shown versus the corresponding measured data in Figure ‎6-6 to 
Figure ‎6-14. Evidently from the figures, the PhATE model was capable of predicting the 
variation in concentrations of PPCPs and EDCs, when actual flows were used, and calibration 
resulted in a significantly better estimation (compared to uncalibrated) of the concentrations in 
the Grand River watershed. The PhATE model simulation had better results while simulating 
ibuprofen, naproxen, carbamazepine, and gemfibrozil compared to other compounds. The 
estimated R-squared values for these drugs ranged from 0.48 for ibuprofen to 0.69 for 
gemfibrozil.  
In April 2008, when there was a peak in the measured concentrations, the model 
simulation failed to reasonably predict the measured concentrations of ibuprofen, naproxen, and 
carbamazepine (showed in Figure ‎6-6 to Figure ‎6-14). The assessment of the flow regime also 
showed that there was a large peak in the flow rate in April 2008, suggesting a higher amount of 
treatment bypass in the watershed or lower efficiency of the treatment plants at that time. 
Evaluation of the calibration results for compounds that were frequently measured below 
the detection limit (e.g., 70% of NP concentrations were reported below the detection limit) was 
challenging. The concentrations reported for observations below detection limit were assumed to 
be equal to the detection limit for the calibration purpose. As shown in Figure ‎6-10, the 
simulated concentrations of NP did not fit the measured data well, so the calibrated parameters in 
Table ‎6-1 might be unreliable. The occasional jumps (peaks) from below detection limit to 
considerable values may suggest the pulse-type release of this industrial compound into the 
environment. It must be mentioned that NP (an endocrine disrupting compound) and DEET (a 
personal care product) have different pathways of entering into the environment other than 
pharmaceuticals. Also, there is an uncertainty in the mass loading of these compounds which 




Figure ‎6-6: Simulated concentrations of ibuprofen before and after calibration compared to its measured concentrations 
 






























































Figure ‎6-8: Simulated concentrations of carbamazepine before and after calibration compared to its measured concentrations 
 





































































Figure ‎6-10: Simulated concentrations of NP before and after calibration compared to its measured concentrations 
 
  
Figure ‎6-11: Simulated concentrations of gemfibrozil before and after calibration compared to its measured concentrations at (a) 















































































































(b) Average Measured Con.
Measured Con.





Figure ‎6-12: Simulated concentrations of bezafibrate before and after calibration compared to its measured concentrations at (a) 
Mannheim and (b) Holmedale 
    
Figure ‎6-13: Simulated concentrations of sulfamethoxazole before and after calibration compared to its measured concentrations at (a) 














































































































































































(b) Average Measured Con.
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Figure ‎6-14: Simulated concentrations of trimethoprime before and after calibration compared to its measured concentrations at (a) 























































































For some cases, the calibrated parameter values reported in Table ‎6-1 seemed to be 
unreasonable- for instance, high variability in in-stream decay value (e.g., two or three orders of 
magnitude), a large difference between removal efficiency of treatment plant in one season in 
compare to other seasons, and a lower removal rate in summer than in winter. These pattern can 
be expressed by some of the following facts: (1) the calibration was performed only at one 
sample location which is mostly effected by secondary treatment plant removal; therefore, in-
stream decay, lagoon, and tertiary treatment plant removal were not sufficiently contributed in 
the calibration; (2) a high percent of observed concentrations for some of the compounds were 
reported below detection limit (e.g., bezafibrate, NP); (3) in the literature, a wide range of values 
was reported for each parameter value, which resulted a high correlation between parameters in 
the calibration exercise.  
 
6.4 Improvement in Modelling through Seasoning 
The prediction of the selected chemicals was improved by considering the seasonality of 
Canadian environments. In order to assess the significance of applying seasonality to the model 
parameters in this study, different annual and seasonal scenarios were considered (see Table 
‎6-2). The average seasonal simulated concentrations of ibuprofen, naproxen, carbamazepine, 
DEET, and NP in all five scenarios were plotted in Figure ‎6-15 along with the measured 
concentrations. The comparison was based on the difference between seasonal average simulated 
concentrations and seasonal average measured concentrations. 
Seasoning parameters showed different results in simulation of the chemicals. In most 
cases, applying seasonal flow (i.e. scenario 2) improved the estimation of the average 
concentrations compared to the average concentrations estimated using average annual flow (i.e. 
scenario 1); however, it yielded overestimation of the average concentrations of ibuprofen and 
naproxen in summer. Scenario 3 slightly improved the modelling; it only led to some 
degradation for NP and naproxen in summer. Seasonality of both loss and loading parameters 
(scenario 4 and scenario 5) significantly improved the simulation of ibuprofen, naproxen, and 
DEET, but it resulted in poor estimation of carbamazepine; this trend can be explained by 
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seasonality in loading of ibuprofen, naproxen, and DEET but relatively constant usage of 
carbamazepine throughout the year.  
As mentioned in the previous section, there were good fits between measured and 
calibrated concentrations when the actual flow rates were used, though the average simulated 
concentrations after calibration (i.e. in scenario 5) were less than the average measured 
concentrations for all of the seasons and compounds. This result suggests that the average flow 
might not be the best strategy in estimating the average concentrations, and other types of central 
tendency measures like median is worth being investigated. Figure ‎6-16 compares the actual 
average and actual median flow rate values at the time of sampling with the average estimated 
flows. There was a good match between the average actual flow and estimated flow, while the 
actual median flow rates were considerably lower than the average flow. As the estimated 
concentrations in all cases were less than the average measured concentrations, accounting for 
the median flow instead of mean flow is expected to increase the simulated concentration values 
and probably improve the average seasonal simulation. 
As another form of comparison, the percentage of the field measured concentrations lying 
between simulated mean flow concentrations and simulated low flow concentrations were 
calculated for each season and reported in Table ‎6-3. Simulation of ibuprofen improved 
considerably after calibration, especially in the fall when the number of measured concentrations 
between the two simulated concentrations increased from 0 in scenarios 1, 2, and 3 to 38 in 
scenario 5. For naproxen, seasoning all parameters improved simulation in the winter and 
summer but decreased the number of measured concentrations within the two predicted 
concentrations in the spring and fall. The highest number of measured concentrations of 
carbamazepine fell between the simulated concentrations when scenario 1 was applied. Scenario 
4 and scenario 5 resulted in better simulation of DEET in the winter and spring but not in the 
summer and fall. Seasoning parameters only improved NP simulation in the winter. Overall it 
can be stated that, for winter and spring, applying seasonal loss parameters and loading (i.e. 
scenario 4 and scenario 5) slightly increased the number of measured concentrations within the 
two predicted concentrations over scenario 1 that employed annual hydrologic and chemical 
parameters. Seasoning loss parameters for fall and summer did not improve the simulation, but 
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seasoning loading for ibuprofen and naproxen in summer increased the percentage of measured 




Table ‎6-2: Different chemical and hydrological scenarios employed for simulations 
Scenarios/Parameters Loss
1
 Loading Flow Comments 
Scenario 1 avg. annual avg. annual 
annual mean and low 
flow 
See section  3.2.1 and section  4.3.2  
Scenario 2 avg. annual avg. annual 






seasonal mean and 
low flow 
average of data measured in each 







seasonal mean and 
low flow See section ‎5.1 and section ‎5.2  
Scenario 5 auto-calibrated avg. seasonal  
seasonal mean and 
low flow 
See section  6.3  
 
1
The loss parameters were in-stream decay, removal efficiency of lagoons, removal efficiency of 







Figure ‎6-15: Simulated concentrations of the compounds using different scenarios compared to the 

















































































































Figure ‎6-15: Simulated concentrations of the compounds using different scenarios compared to the 










































































Figure ‎6-16: Comparison of average and median flows versus season 
 
Table ‎6-3: Percentage of measured concentration data lying between the simulated low flow-based 
and mean flow-based concentrations 
Compounds Season Scenario 1 Scenario2 Scenario 3 Scenario 4 Scenario 5 
Ibuprofen 
Winter 55 55 65 40 60 
Spring 41 56 56 56 52 
Summer 0 0 0 17 38 
Fall 46 21 38 33 50 
Naproxen 
Winter 45 45 65 60 50 
Spring 78 59 81 70 81 
Summer 42 8 0 46 33 
Fall 71 63 21 58 50 
Carbamazepine 
Winter 80 80 85 - 70 
Spring 78 78 78 - 70 
Summer 96 63 67 - 63 
Fall 100 92 92 - 50 
DEET 
Winter 40 40 - 65 60 
Spring 26 37 - 37 26 
Summer 67 46 - 42 33 
Fall 75 42 - 38 46 
NP 
Winter 40 40 50 - - 
Spring 30 19 26 - - 
Summer 29 25 4 - - 

























6.5 PhATE Model Validation 
As mentioned previously, the PhATE parameters for each compound of interest were calibrated 
using a split-sample subset of available observation data for the Grand River watershed. 
Following calibration, the parameters were validated with data that was not used for calibration. 
Ibuprofen, naproxen and carbamazepine were the only compounds that validation phase was 
conducted for.  
In the validation phase, ibuprofen, naproxen, and carbamazepine were simulated using 
the calibrated parameters and actual flows at the time of sampling. As the actual flow data at the 
time of sampling were not reported, to obtain the actual flow values, the flow data at the Doon 
and Brantford stations, the closest GRCA and WSC monitoring sites to the sample sites, were 
used. Figure ‎6-17 shows the simulated concentrations of ibuprofen, naproxen, and 
carbamazepine along with the corresponding measured concentration values.  
For carbamazepine, as shown in Figure ‎6-17, there was a good fit between the simulated 
concentrations and the measured data at both sampled locations with the exception of the August 
sample event at Holmedale , when the measured concentration was extremely high (outlier), 
about 1μg/L. For ibuprofen, the simulated concentrations and the measured concentrations had a 
good fit Mannheim, while the simulated data at Holmedale did not match the measured data 
sufficiently well. The better model performance for Mannheim was probably due to the fact that 
the calibration was also performed on this segment and Holmedale was not considered in 
calibration. Note that this behaviour (different accuracies in segment 36 and segment 65) was not 
observed for carbamazepine possibly because this compound is relatively persistent in the 
environment. Therefore, the variation in carbamazepine concentration is generally governed by 
the variation in the flow rate. The validation results for naproxen were not as good as the 
validation results for ibuprofen and carbamazepine. 
Although the accuracy in validation might not seem very high, the predicted and 
measured concentrations of this class of chemicals are suggested to have a favorable match as 
the predicted data is within a factor of 10 of the measured data [17]. According to this reference, 
the validation results in this study indicated relatively good fits between observed data and 








































































































































































































6.6 Identifying Segments with High Potential Risk 
The concentrations of PPCPs and EDCs were predicted both spatially and temporally for the 
entire Grand River watershed. The PhATE model was used to predict the highest risk areas in 
terms of negatively impacting aquatic ecosystems in the different seasons. Determining high risk 
location is a valuable procedure for designing cost-effective field sampling plans [47] and in 
controlling and managing the treatment plants in the watershed. 
In this regard, concentrations of the selected PPCPs and EDCs (i.e. ibuprofen, naproxen, 
carbamazepine, DEET, bezafibrate, gemfibrozil, trimethoprim) were predicted seasonally in 
mean and low flow conditions for the entire watershed, using the calibrated parameters 
(presented in section ‎6.3 ). Stream segments with high potential risk were identified using the 
―dirty dozen‖ approach, which is a popular approach used for a variety of purposes. For example, 
it has been used for the following purposes: (1) identifying septic tank installations which 
violated water quality protection rules [140]; (2) investigating highly halogenated organics that 
may arise environmental or human health problems [141]; defining high priority toxic chemicals 
that have been prohibited from use [142]; (4) detecting property owners with the highest 
violation of building code [143], etc. In this study, the ―dirty dozen‖ was defined as the twelve 
segments in the watershed with the highest concentrations of the chemicals.  
For each compound of interest and in each season, and for low flow and mean flow 
conditions, the dirty dozen segments were identified, separately. The outcome of this analysis 
consisted of two sets of stream segments with high potential risk associated with low flow and 
mean flow conditions. Each stream segment set was the union of all dirty dozen segment sets for 
the different compounds and different seasons and are shown in Figure ‎6-18 and Figure ‎6-19, 
respectively. The number of segments with high potential risk in the low flow condition (27 
stream segments) was greater than that in the mean flow condition (20 stream segments); thus, 
there was a larger variability of concentrations of the compounds in the low flow condition.  
As can be seen in the figures, a majority of high risk areas in the Grand River are in the 
stream segment portion between the point where wastewater from the Waterloo and Kitchener 
treatment plants discharge into the stream and Brantford. Also, the Speed River, after receiving 
effluent from the Guelph wastewater treatment plant is expected to be at high risk of exposure to 
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the chemicals. The streams exposed to the effluent of the treatment plants at Dundalk, Elmira, 
Baden, and Brant are at risk for short distances, but after a few kilometers (flowing downstream), 
the estimated concentrations are reduced. This is due to dilution and, to a lesser extent, 
degradation of the compounds and their sorption to solids.  
The ranges of the simulated concentrations for the dirty dozen segments associated with 
different compounds are presented in Table ‎6-4. According to this table, for ibuprofen, naproxen, 
and bezafibrate, the highest concentrations associated with mean flow are more likely to happen 
in winter and fall; while for carbamazepine, DEET, gemfibrozil, and trimethoprim, the highest 
concentrations in mean flow will occur in summer. In the low flow condition, a clear seasonal 
variability pattern in the concentrations was not observed, and stream segments may be exposed 
to high concentrations any time of the year. 
 
Table ‎6-4: Ranges of predicted concentrations in dirty dozen segments 
 Compound  Flow regime Winter Spring Summer Fall 
Ibuprofen  
mean flow 67-87 28-65 16-54 47-90 
low flow 265-458 98-447 46-207 133-568 
Naproxen  
mean flow 47-150 28-76 28-75 46-79 
low flow 136-724 86-479 50-138 143-304 
Carbamazepine  
mean flow 20-29 10-16 63-91 26-37 
low flow 74-164 46-76 151-387 90-271 
DEET  
mean flow 11-66 22-88 81-405 24-129 
low flow 23-247 58-392 138-767 46-418 
Bezafibrate  
mean flow 8-10 4-5 4-7 6-9 
low flow 31-53 18-37 10-42 20-62 
Gemfibrozil  
mean flow 4-6 2-4 3-7 2-5 
low flow 13-24 9-20 6-14 9-39 
Trimethoprim  
mean flow 8-16 3-12 5-21 5-24 













6.7 Potential Risk of PPCP toxicity to Grand River Aquatic Species 
The potential for the selected compounds to exert toxicity was assessed by comparing the 
maximum predicted concentrations of PPCPs throughout the watershed (given in Section ‎6.3 ) to 
corresponding minimum effect concentrations reported in the literature (presented in Section ‎2.5 
). The European Commission (European Union) and U.S. Food and Drug Administration (FAD) 
proposed regulatory guidelines in order to assess the toxicological risk of pharmaceuticals in the 
environment. In this study, the toxicity of these compounds was assessed following these 
guidelines.  
The cut-off values for PPCPs to undergo a risk assessment are 1μg/L and 0.001 μg/L in 
the US and EU [37, 144], respectively. If measured or predicted environmental concentrations 
exceed these cut of values, it is recommended that the toxicity potential of these compounds 
should be evaluated. As shown in Table ‎6-5, the maximum predicted concentrations of all the 
compounds were less than the US cut-off value but exceeded the EU cut-off value. Therefore, 
according to the US guideline, no further assessment is required; however, according to EU, the 
assessment should be continued to the next step. As suggested in the EU regularity guideline, in 
the next tier of risk assessment, the hazard quotient (HQ) assessment was performed in this 
study. The HQ was calculated as the ratio of the maximum predicted concentration to the lowest 
effect concentration multiplied by an assessment factor. The assessment factor was used because 
of the lack of enough acute and chronic toxicity effects in the literature and uncertainty in the 
predicted concentration; in the EU, an assessment factor of up to 1000 is suggested to account 
for uncertainty [144]. For the compounds with an HQ of less than one, no further assessment is 
required. Conversely, the compounds with an HQ greater than one may require regulations or 
restrictions. Importantly, for all the selected compounds except gemfibrozil, the calculated HQ 
values were greater than one, suggesting that further investigation may be necessary to address 


















ibuprofen 1-100 μg/L 
0.568 
568 [56] 
ibuprofen 10 ng/L 56800 [60] 
ibuprofen 1 mg/L 0.57 [54] 
naproxen 2.6 mg/L 
0.724 
0.28 [54] 
naproxen 0.33 mg/L 2.19 [61] 
carbamazepine 3.76 mg/L 
0.387 
0.10 [54] 
carbamazepine 10 ng/L 38700 [60] 
carbamazepine 1 μg/L 387 [59] 
gemfibrozil 1 mg/L 
0.039 
0.04 [54] 
gemfibrozil 1.76 mg/L 0.02 [54] 
gemfibrozil 0.53 mg/L 0.07 [61] 
bezafibrate 1 mg/L 
0.062 
0.06 [54] 
bezafibrate 0.047 mg/L 1.32 [61] 
sulfamethoxazole 0.21 mg/L 
0.254 
1.21 [61] 
sulfamethoxazole 0.52 mg/L 0.49 [61] 
sulfamethoxazole 1-10 μg/L 254 [51] 






Chapter 7  
Summary and Conclusions 
7.1 Summary 
This study employed the PhATE model to seasonally predict transport of frequently detected 
pharmaceuticals, personal care products, and endocrine disruptors in the Grand River watershed. 
The simulations were performed under two flow regimes, mean flow and low flow. In the 
uncalibrated phase (i.e., using the default of previously published parameter values), the range 
defined by the simulated concentrations at the two flow conditions for each compound covered 
more that 50% of the measured concentrations.  
Moreover, this project was undertaken to calibrate and validate the model parameters to 
obtain the most probable seasonal parameters for the case study.  
As mentioned previously, calibration was conducted so that a good fit between average 
simulated concentrations and average measured concentrations would be obtained. In this study, 
equal weights were assumed in calibration for all observations. However if worst case conditions 
are of interest and prediction of the highest concentrations happening is required, in calibration, a 
higher weight should be assigned for these high concentrations. Also, results of calibration 
indicated that simulation of drugs with continuous use by humans (e.g., ibuprofen, naproxen, 
carbamazepine, gemfibrozil) was more accurate than the simulation of the compounds that are 
consumed for industrial and agricultural use (e.g., NP and DEET).  
In the validation phase, the performance of the calibrated PhATE model was tested with a 
set of data that was not used in calibration at two sampling sites. Comparing the measured and 
simulated concentrations of carbamazepine showed overall, the simulated concentrations 
matched the measured data at both sampled locations. The simulated and measured 
concentrations of ibuprofen had a good fit at the sample site at which calibration was conducted, 
but were less well fit at the other sample site. The validation results for naproxen were not as 
good as the validation results for ibuprofen and carbamazepine. 
Moreover, the present study was designed to identify stream segments with high potential 
risk of being exposed to the selected PPCPs and EDCs in the watershed in different seasons. The 
72 
 
results of this investigation suggested that the highest concentrations of the compounds are likely 
to occur in a portion of the Grand River extending from the effluents of the Waterloo and 
Kitchener wastewater treatment plants downstream to the municipality of Brantford and also a 
portion of the Speed River after receiving the effluent from the Guelph wastewater treatment 
plant. The streams exposed to the effluent of the treatment plants at Dundalk, Elmira, Baden, and 
Brant are also expected to have a higher risk for short distances, but the concentrations reduced 
after a few kilometers due to dilution and degradation. 
Finally, to assess the toxicity potential of the selected compounds, the maximum 
predicted concentrations of PPCPs throughout the watershed were compared to the minimum 
effect concentrations reported in the literature. Simulation results showed that the concentrations 
of the selected compounds were less than the US cut-off value for risk assessment, and no further 
assessment is required for these compounds using this metric. However, according to EU 
regulatory guidelines, most of the PPCPs (i.e., ibuprofen, naproxen, carbamazepine, bezafibrate, 
sulfamethoxazole) were predicted to be at concentrations which require further assessment 
and/or more stringent regulations and restrictions.  
7.2 Conclusions 
The modified PhATE model was found to be capable of accurately simulating pharmaceutical 
concentrations in the Grand River watershed. The model tended to over predict concentrations, 
and where model predictions were poorly matched to the measured data, the misfits tended to be 
due to the model over-predicting rather than under-predicting. Indeed, accounting for seasonal 
variability in parameters improved the accuracy of the PhATE model.  
The PhATE model, when actual flow and the calibrated parameters were used, accurately 
predicted pharmaceutical concentrations in the Grand River. From these findings it can be 
pointed out that the hydrologic parameters, flow and velocity, are the most important parameters 
for estimation of PPCPs and EDCs in the surface water. Interestingly, if the fluctuation in 
concentrations is described by flow variability, the model could simulate concentrations well, 
while when the variation in concentrations is due to other factors such as loss parameters, the 
model could not predict the concentrations well enough. For example, carbamazepine, a 
persistent compound in the environment, has relatively low and constant removal rate values; 
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therefore, the variation in carbamazepine concentration is generally governed by the variation in 
the flow rate. As such, the results showed a good fit between the simulated and measured 
concentrations of carbamazepine. Accordingly, the results confirmed that a better estimation of 
the hydrological parameters would improve the simulation accuracy of any compound in the 
surface water but to different extents. 
The validation results showed relatively good fit between the measured data and corresponding 
model output, and the deviations of the simulated concentrations from the measured data were 
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Daily measured concentrations reported by [43] and [42] 
Table A-1: Measured Concentration of PPCPs and EDCs from [43]  
(to be continued) 
Date DEET ibuprofen nonylphenol naproxen Carbamazepine 
Nov.13 21 8 nd 13 d 
Nov.27 53 10 nd 17 d 
Jan.24 22 84 d 104 18 
Jan.31 23 60 46 91 23 
Feb.7 16 107 31 108 18 
Feb.14 d 144 nd 147 57 
Feb.21 16 100 na 104 26 
Feb.28 d 81 d 187 30 
Mar.6 16 91 nd 126 26 
Mar.14 32 104 nd 70 d 
Mar.22 d 32 nd 27 nd 
Mar.28 d 11 nd 8 nd 
Apr.5 19 58 d 43 d 
Apr.12 16 111 nd 59 d 
Apr.19 d 114 nd 66 d 
Apr.26 80 179 80 143 56 
May.3 16 39 d 50 d 
May.9 34 35 nd 74 21 
May.16 41 26 nd 27 d 
May.23 219 36 d 78 24 
May.30 154 30 nd 81 29 
Jun.13 138 8 d 53 30 
Jun.20 107 17 d 57 25 
Jul.5 165 D d 21 60 
Jul.18 97 D 28 18 33 
Jul.20 73 7 77 14 26 
Jul.24 133 D d 19 32 
Jul.26 101 d d 19 27 
Aug.1 105 d nd 13 38 
Aug.8 208 15 nd 17 23 
Aug.13 86 d nd 19 32 
Aug.15 133 11 nd 31 32 
Aug.17 62 9 nd 27 31 
Aug.22 45 7 na 24 40 
Aug.24 54 15 nd 21 35 
Aug.29 52 9 46 14 37 
Aug.31 39 8 85 12 40 
Sep.6 49 11 37 17 33 
Sep.10 50 18 42 19 33 
Sep.12 41 17 na 18 28 
Sep.14 72 33 na 42 35 
Sep.17 69 12 25 30 26 
Sep.19 44 22 55 34 44 
Sep.21 106 33 162 48 30 
Sep.24 109 50 44 45 29 
Sep.27 94 31 31 40 29 
Oct.2 122 44 d 40 30 
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Table A-2: Measured Concentration of PPCPs and EDCs reported by [43] 
(continued) 
Date DEET ibuprofen nonylphenol naproxen Carbamazepine 
Oct.4 92 38 nd 82 34 
Oct.11 58 15 131 40 23 
Oct.15 45 40 d 79 39 
Oct.18 27 22 nd 57 26 
Oct.25 30 24 nd 52 32 
Oct.30 28 22 82 43 30 
Nov.1 44 22 39 54 33 
Nov.12 23 111 d 58 31 
Nov.14 38 56 117 72 28 
Nov.19 38 56 nd 77 25 
Nov.28 57 95 nd 118 25 
Nov.30 42 95 nd 127 27 
Dec.5 41 51 79 88 18 
Dec.12 48 95 33 175 37 
Dec.15 44 154 nd 138 32 
Dec.19 45 134 nd 170 34 
Jan.16 d d 40 6 d 
Jan.21 39 42 83 56 d 
Jan.23 54 51 nd 61 d 
Jan.30 34 30 nd 36 d 
Feb.6 19 21 nd 15 nd 
Feb.8 d 13 106 57 nd 
Feb.13 79 61 nd 48 d 
Feb.19 12 12 59 44 d 
Feb.21 d 15 na 12 nd 
Feb.26 20 29 48 25 d 
Mar.4 d 31 52 25 nd 
Mar.6 d 22 na 28 d 
Mar.12 nd 30 nd 36 d 
Mar.19 18 19 na 24 d 
Mar.27 16 36 d 36 d 
Apr.3 nd 9 34 6 nd 
Apr.11 nd 7 nd 11 nd 
Apr.16 26 20 39 31 d 
Apr.24 21 18 nd 46 d 
Apr.30 33 9 nd 55 18 
May.7 26 9 d 33 d 
May.14 42 d nd 73 21 
May.21 96 11 nd 60 19 
May.28 152 17 na 43 23 
Jun.4 128 8 nd 39 20 
Jun.10 399 d nd 32 30 
Jun.19 65 d nd 21 d 
Jun.25 64 nd na 32 32 
Jul.10 78 7 nd 36 23 
Jul.15 71 d nd 32 18 
Jul.23 62 8 na 13 d 
Aug.6 152 21 nd 35 22 




Table A-3: Measured concentration of PPCPs from Grand River near Mannheim reported by [42] 
Month 
Compound 
Apr-05 May-05 Jun-05 Jul-05 Aug-05 Sep-05 Oct-05 Nov-05 Dec-05 Jan-06 Feb-06 Mar-06 
Ibuprofen 
replicate 1 <LOQ <LOQ <LOQ 30.8 <LOQ 31.9 29.8 22.7 29.6 27.1 15.8 32.9 
replicate 2 <LOQ <LOQ <LOQ 20.9 <LOQ 26.5 32.4 27.3 27.4 22.7 17.1 33.2 
naproxen 
replicate 1 6.3* 21 30 26 12 38 47 27 33 26 11 25 
replicate 2 15 19 31 29 13 54 42 34 36 23 9.7* 29 
carbamazepine 
replicate 1 2.8 7.6 25.1 27 21.6 15.9 19.1 30.1 10.8 7.1 3.2 12.2 
replicate 2 2.7 7.1 22.4 28.1 20.1 17.1 18.1 21.5 11.2 8.5 2.8 12.1 
gemfibrozil 
replicate 1 1 1.4 2.8 3.5 1.9 1.8 2.1 2.7 1.4 1.5 1.2 2.2 
replicate 2 1.1 1.3 1.7 3.7 1.5 1.6 2.3 1.9 <LOQ 1.7 1.2 2.2 
bezafibrate 
replicate 1 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 5.3 <LOQ <LOQ <LOQ <LOQ 
replicate 2 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 5.2 <LOQ <LOQ <LOQ <LOQ 
sulfamethoxazole 
replicate 1 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 21 25 <LOQ <LOQ <LOQ <LOQ 
replicate 2 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 26 26 <LOQ <LOQ <LOQ <LOQ 
trimethoprim 
replicate 1 0.4* 4.1* 7.5* 5.7* 3.6* 1.7* 14 11 4.7* 4.1* 2.6* 4.0* 








Table A-4: Measured concentration of PPCPs from Grand River near Holmedale reported by [42] 
Month 
Compound 
Apr-05 May-05 Jun-05 Jul-05 Aug-05 Sep-05 Oct-05 Nov-05 Dec-05 Jan-06 Feb-06 Mar-06 
Ibuprofen 
replicate 1 <LOQ <LOQ <LOQ 8.7 <LOQ 12.5 15.8 33.8 20.3 28.7 35 53.5 
replicate 2 <LOQ <LOQ <LOQ 10.1 <LOQ <LOQ 14.4 25.9 23.8 28.2 38.3 59.6 
naproxen 
replicate 1 16 10 8.7* 11 4.8* 14 16 34 20 8.6* 18 64 
replicate 2 5.1* 12 12 12 9.6* 14 6.3* 30 28 21 17 64 
carbamazepine 
replicate 1 7.9 14.4 52.1 71.9 1015.6 50.9 32.7 42.3 18.4 19.1 8.2 26.8 
replicate 2 7.6 13.6 53.1 67.1 961 51.7 31.3 42.9 20.7 15.5 7.9 28.6 
gemfibrozil 
replicate 1 1.4 3.9 3 3.3 2.3 2.6 2.8 5.1 2.1 2.7 1.9 5.9 
replicate 2 1.7 2 4.7 3.4 2.2 3.7 3.2 4.3 3.2 3.1 1.4 6 
bezafibrate 
replicate 1 <LOQ <LOQ <LOQ <LOQ <LOQ 5.3 <LOQ 11 8.2 6.9 <LOQ 12 
replicate 2 5.2 <LOQ <LOQ <LOQ <LOQ 6 <LOQ 12 7.6 7 <LOQ 12 
sulfamethoxazole 
replicate 1 <LOQ <LOQ 24 24 21 31 29 35 <LOQ <LOQ <LOQ 27 
replicate 2 <LOQ <LOQ 24 24 21 30 32 35 <LOQ <LOQ <LOQ 28 
trimethoprim 
replicate 1 2.8* 3.6* 6.9* 3.8* 2.2* 2.2* 6.5* 6.2* 8.1* 1.4* 3.7* 5.8* 





Water Flow Stations 
















2GA038 NITH RIVER ABOVE NITHBURG 30 513285 4814373 0.00 43.48 
2GA018 NITH RIVER AT NEW HAMBURG 55 523406 4802541 -80.71 43.38 
2GA028 CONESTOGO RIVER AT GLEN ALLAN 47 523995 4833359 -80.70 43.65 
2GA042 MOOREFIELD CREEK NEAR ROTHSAY 17 522848 4851382 -80.72 43.82 
2GA039 CONESTOGO RIVER ABOVE DRAYTON 31 529166 4847658 -80.64 43.78 
2GA043 HUNSBERGER CREEK NEAR WILMOT CENTRE 16 530340 4801075 -80.63 43.36 
2GA030 ALDER CREEK NEAR NEW DUNDEE 45 536354 4802015 -80.55 43.37 
2GA024 LAUREL CREEK AT WATERLOO 41 539254 4813121 -80.51 43.47 
2GA023 CANAGAGIGUE CREEK NEAR ELMIRA 50 539618 4825134 -80.51 43.58 
2GA010 NITH RIVER NEAR CANNING 56 544259 4781806 -80.46 43.19 
2GA034 GRAND RIVER AT WEST MONTROSE 39 541850 4825716 -80.48 43.59 
2GB008 WHITEMANS CREEK NEAR MOUNT VERNON 45 550126 4774800 -80.38 43.13 
2GA016 GRAND RIVER BELOW SHAND DAM 57 552951 4841983 -80.34 43.73 
2GA041 GRAND RIVER NEAR DUNDALK 17 550939 4887399 -80.36 44.14 
2GB001 GRAND RIVER AT BRANTFORD 56 559611 4775538 -80.27 43.13 
2GA003 GRAND RIVER AT GALT 57 555433 4800047 -80.32 43.35 
2GA015 SPEED RIVER BELOW GUELPH 57 559729 4819320 -80.26 43.53 
2GA040 SPEED RIVER NEAR ARMSTRONG MILLS 31 558871 4831890 -80.27 43.64 
2GA014 GRAND RIVER NEAR MARSVILLE 47 558473 4856536 -80.27 43.86 
2GB007 FAIRCHILD CREEK NEAR BRANTFORD 43 568707 4777304 -80.16 43.15 
2GA029 ERAMOSA RIVER ABOVE GUELPH 44 566017 4821769 -80.18 43.55 
2GA031 BLUE SPRINGS CREEK NEAR EDEN MILLS 41 571923 4824963 -80.11 43.58 
2GB010 MCKENZIE CREEK NEAR CALEDONIA 46 585525 4764893 -79.95 43.03 
2GA037 SCHNEIDER CREEK AT KITCHENER 22 542393 4809528 -80.48 43.44 








Average seasonal flow 
 
 
Figure C-1: Avg. seasonal flow versus drainage area for segments with drainage area > 1200km
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Low seasonal flow 
 
 
Figure C-4: Low seasonal flow versus drainage area for segments with drainage area > 1200km
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Simulated Concentration versus cumulative measured concentration 
  


























































































































































































































































































































































































































































































































































































































































Segments Number Through the Grand River
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Figure E-2: The sum of squared differences of naproxen concentrations at different levels 
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Figure E-3: The percent contribution of parameters on the concentrations of carbamazepine 
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Figure E-4: The sum of squared differences of carbamazepine concentrations at different levels 
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Figure E-6: The sum of squared differences of gemfibrozil concentrations at different levels 
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Figure E-7: The percent contribution of parameters on the concentrations of sulfamethoxazole 
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Figure E-8: The sum of squared differences of sulfamethoxazole concentrations at different levels 
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Figure E-9: The percent contribution of parameters on the concentrations of trimetoprime (No 
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Removal Efficiency by Tertiary Treatment Plants
